Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
AIN HOLDINGS rebounds on higher prescription prices, FY April 2026 earnings exceed plan
Shares of AIN HOLDINGS INC. <9627> rebounded on Tuesday after the company announced that its full-year consolidated earnings for the fiscal year ended April 2026 beat its previous forecasts. Sales reached 647.5 billion yen (up 41.7% year-on-year) against the prior estimate of 646.0 billion yen. Operating profit rose to 29.5 billion yen (up 74.9%) from 28.3 billion yen, while net profit climbed to 17.0 billion yen (up 83.6%) from 13.5 billion yen.
Earnings were driven by higher prescription unit prices from high-value pharmaceuticals and steady volume growth in the core pharmacy business. Smooth post-merger integration (PMI) at Sakura Pharmacy Group, which joined the company on Aug. 1, 2025, also lifted results. Alongside the upward revision, AIN HOLDINGS raised its year-end dividend forecast to 100 yen per share from 80 yen.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
NS TOOL rebounds for first time in six days on price hike announcement for some products from August orders
201 stocks rise, 1,332 fall on Tokyo Stock Exchange Prime Market as of 10:00 a.m.
Takashimaya rebounds as May domestic department store sales rise 10.8% in double-digit growth
ZETA INC. rebounds on Coop Tohoku's adoption of ZETA SEARCH
Tsubota Laboratory hits record low on dilution concerns from stock warrant issuance
QD Laser surges limit-up on business collaboration with TDK Corporation <6762>, turns to profit forecast
Yamadai hits daily limit up on Nice Corporation's TOB offer at 601 yen
KANAMOTO shares rise near all-time high on upward earnings revision
ITO EN plunges for first time in 5 days, hitting new year-to-date low on 8% operating profit decline forecast amid soaring green tea material costs
Heartseed surges to daily limit up following positive phase 1/2 trial results for allogeneic iPS cell-derived cardiac spheroids